Advanced Search: Mutation Specific

For more information about any of the clinical trials listed on this site, call 314-747-7222 or 800-600-3606 toll free or email Patient_Care_Coordination_Center@bjc.org.

Select Basic Search to view clinical trials grouped by category and Advanced Search to be able to further narrow search results.

 

202112042

EPIK-B4: A phase II, multi center, randomized, open-label, active controlled study to assess the safety and efficacy of dapagliflozin + metfromin XR versus metformin XR during treatment with alpelisib (BYL719) in combination with fulvestrant in participants with HR+, HER2-, advanced Breast Cancer with a PIK3CA mutation following progression on/after endocrine-based therapy

202108130

A Phase III, Double-blind, Randomised Study to Assess Switching to AZD9833 (a Next Generation, Oral SERD) + CDK4/6 Inhibitors(Palbociclib or Abemaciclib) vs Continuing NSAI + CDK4/6 Inhibitorsin HR+/HER2- MBC Patients with Detectable ESR1 Mutation Without Clinical or Radiological Progression During 1L Treatment with NSAI +CDK4/6 Inhibitor